| 5.48 0.43 (8.51%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.81  |
1-year : | 7.65 |
| Resists | First : | 5.83 |
Second : | 6.55 |
| Pivot price | 5.34 |
|||
| Supports | First : | 4.67 | Second : | 3.89 |
| MAs | MA(5) : | 5.19  |
MA(20) : | 5.45 |
| MA(100) : | 8.23 |
MA(250) : | 20.29 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 39.8 |
D(3) : | 34.5 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 50.4 | Low : | 4.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LENZ ] has closed below upper band by 41.1%. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.5 - 5.53 | 5.53 - 5.55 |
| Low: | 4.97 - 5 | 5 - 5.02 |
| Close: | 5.43 - 5.48 | 5.48 - 5.52 |
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Fri, 24 Jul 2026
LENZ Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview - TradingView
Fri, 24 Jul 2026
LENZ|LENZ Therapeutics Inc|Price:5.030|Chg%:-0.310 - TradingKey
Fri, 24 Jul 2026
LENZ Therapeutics (LENZ) Q1 2026 earnings summary - Quartr
Thu, 23 Jul 2026
LENZ Therapeutics (LENZ) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
Wed, 22 Jul 2026
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline - Yahoo Finance
Tue, 21 Jul 2026
LENZ Therapeutics (LENZ) Leerink Global Healthcare Conference 2026 Summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 1.848e+007 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 10,230 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1798e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 321.6 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 2.099e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -30.69 |
| EBITDA (p.s.) | 1.2037e+007 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.18 |
| Price to Cash Flow | 1.12 |
| Dividend | 0 |
| Forward Dividend | 1.043e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2026-07-21 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|